Skye Bioscience moving ahead with SBI-100 clinical trial after positive safety review

About this update from Skye Bioscience, Inc.

[{"type":"text","content":"--News Direct--Skye Bioscience CEO Punit Dhillon joins Proactive's Natalie Stoberman to discuss the positive safety review for its Phase 2 clinical trial for its SBI-100 Ophthalmic Emulsion. Dhillon said the trial's safety review committee has recommended that the trial continue without modification. Now, the company is preparing for Phase 3 recruitment for the third cohort of eight participants with dosing planned for March.Contact DetailsProactive Investors US+1 [email protected] source version on newsdirect.com: https://newsdirect.com/news/skye-bioscience-moving-ahead-with-sbi-100-clinical-trial-after-positive-safety-review-305519961","length":1204,"tagName":"div"}]

More updates from Skye Bioscience, Inc.